DEPLOYDatabase

Company

Vicarious Surgical

Vicarious Surgical is a US surgical-robotics startup (Waltham, MA; SPAC-listed 2021, NYSE: RBOT) developing the V1 single-port robotic surgery system that uses…

Track Vicarious Surgical
Founded
2014
HQ
Waltham, Massachusetts, USA
Status
distressed (going-concern; NYSE-delisted Mar 2026; OTCQB: RBOT)

Models

1

Overview

Vicarious Surgical is a US surgical-robotics startup (Waltham, MA; SPAC-listed 2021, NYSE: RBOT) developing the V1 single-port robotic surgery system that uses miniature robots that enter the body through a single incision, miniaturizing surgical robotics.

Verified record

Verified deployments
None on file
Active incidents
None on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

Product

V1 single-port robot (9-DoF instrument + VR interface); pre-commercial, no FDA submission.

Status

Going-concern; cash thru Q2 2026; NYSE-delisted Mar 2026. RE-VERIFY soon.

Listing history

SPAC-listed in 2021 under ticker RBOT

Current market

Now traded on OTCQB

Data & sources

Press releases

1

News coverage

1

Web sources

1

3 sources backing this record.View all →

Models (1)

View all models →

Current platform

V1

Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.

surgicalView model →

Vicarious Surgical on the deployment map

Where Vicarious Surgical's robots are verified operating. Explore the deployment map by place and type.

Relationships

DD8 Holdings Corp.InvestorKKhosla VenturesInvestor

Explainers

Plain-language answers to the questions people ask about Vicarious Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is a surgical robot?

    A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.

Founders (3)

  • Adam Sachscofounderfounded 2014-01-01no longer at company
  • Sammy Khalifacofounderfounded 2014-01-01no longer at company
  • Barry Greenecofounderfounded 2014-01-01no longer at company

Former / Previously (3)

  • Adam Sachs Co-founder & CEO2014 to 2024secondary-verified
  • Sammy Khalifa Co-founder & CTO2014 to 2024reported, not verified
  • Barry Greene Co-founder, Medical Advisor2014 to 2024reported, not verified

Safety record

No incidents on record for Vicarious Surgical.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Vicarious Surgical in third-party press

Another SPAC Failure: Vicarious Surgical Board Recommends Company Dissolution

Jul 16, 2026

Vicarious Surgical board proposes dissolving the company - MedTech Dive

Jul 15, 2026

Vicarious Surgical board seeks to dissolve company - The Robot Report

Jul 15, 2026

Peer companies